Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TDO2 | P48775 | 2/20 | 0.38 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.38 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257268 | 0.87 | PNMT (0.42) | NISCHAVPR2AVPR1AIDO1TDO2 | |
| SCHEMBL3815968 | 0.87 | CASP1 (0.39) | NISCHCASP1AVPR2AVPR1AAOC3 | |
| SCHEMBL19236084 | 0.85 | CASP1 (0.44) | NISCHCASP1AVPR2AVPR1AAOC3 | |
| SCHEMBL28990562 | 0.84 | MAPT (0.38) | NISCHCASP1AVPR2AVPR1AAOC3 | |
| SCHEMBL12561078 | 0.84 | CYP1A2 (0.46) | NISCHCASP1AVPR2AVPR1AAOC3 | |
| SCHEMBL8741030 | 0.84 | CYP1A2 (0.46) | NISCHCASP1AVPR2AVPR1AAOC3 | |
| SCHEMBL28990608 | 0.83 | CASP1 (0.40) | NISCHCASP1AVPR2AVPR1AAOC3 | |
| SCHEMBL28990747 | 0.81 | MAPT (0.37) | CASP1AVPR2AVPR1AAOC3CXCL8 | |
| SCHEMBL28990701 | 0.81 | MAPT (0.37) | CASP1AVPR2AVPR1AAOC3CXCL8 | |
| SCHEMBL28990632 | 0.80 | CASP1 (0.38) | NISCHCASP1AVPR2AVPR1AAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9180120-B2 | Substituted N-phenethyltriazoloneacetamides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9180120-B2 | Substituted N-phenethyltriazoloneacetamides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9180120-B2 | Substituted N-phenethyltriazoloneacetamides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| EP-2619188-B1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | BAYER IP GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-20130225646-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225646-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225646-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| WO-2012028644-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225646-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | TNNT2, TNNI3, PNMT | NISCH 317/4885CASP1 668/4885DPP4 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.